CN Patent

CN104860948A — 咪唑并嘧啶酮类化合物及其制备方法和应用

Assigned to Nanjing Gai Te Medical Science Co Ltd · Expires 2015-08-26 · 11y expired

What this patent protects

本发明公开了式(I)所示咪唑并嘧啶酮类化合物及其制备方法和应用。其中，n、R和Ar如说明书所述，本发明的化合物及其药学上可接受的盐可以激发人体肿瘤坏死因子相关凋亡诱导配体的产生，同时能避免现有基于重组蛋白和抗体的治疗方式的弊端，从而为相关肿瘤的治疗提供新的选择。

USPTO Abstract

本发明公开了式(I)所示咪唑并嘧啶酮类化合物及其制备方法和应用。其中，n、R和Ar如说明书所述，本发明的化合物及其药学上可接受的盐可以激发人体肿瘤坏死因子相关凋亡诱导配体的产生，同时能避免现有基于重组蛋白和抗体的治疗方式的弊端，从而为相关肿瘤的治疗提供新的选择。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN104860948A
Jurisdiction: CN
Classification: —
Expires: 2015-08-26
Drug substance claim: No
Drug product claim: No
Assignee: Nanjing Gai Te Medical Science Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.